Cathie Wood's ARK Invest made a series of end-of-year portfolio adjustments on the second final trading day of 2025, tilting further toward biotechnology while

MENLO PARK, Calif., Dec. 30, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be presenting at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 10:30 AM PT (1:30 PM ET) in San Francisco, California.

Cathie Wood's Ark Invest increased stakes in gene-editing and autonomous mobility companies while trimming holdings in Tesla (TSLA) and Rocket Lab (RKLB).Sellin

Shares of Pacific Biosciences of California, Inc. (NASDAQ: PACB - Get Free Report) dropped 5.1% during trading on Friday. The stock traded as low as $1.79 and last traded at $1.7850. Approximately 1,827,647 shares changed hands during trading, a decline of 80% from the average daily volume of 9,124,740 shares. The stock had previously closed

Pacific Biosciences of California, Inc. (NASDAQ: PACB - Get Free Report) was the target of some unusual options trading on Monday. Stock traders acquired 8,267 call options on the stock. This represents an increase of approximately 231% compared to the average volume of 2,497 call options. Pacific Biosciences of California Stock Down 1.1% NASDAQ PACB opened

MENLO PARK, Calif., Nov. 28, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will participate in a fireside chat at Piper Sandler's 37th Annual Healthcare Conference on Wednesday, December 3, 2025, at 11:30 AM ET in New York, NY.

Pacific Biosciences of California, Inc. (NASDAQ: PACB - Get Free Report) has earned a consensus recommendation of "Hold" from the seven analysts that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and three have given a buy recommendation

Pacific Biosciences of California, Inc. (NASDAQ: PACB - Get Free Report)'s share price crossed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $1.39 and traded as high as $1.67. Pacific Biosciences of California shares last traded at $1.65, with a volume of 6,137,538 shares traded. Analysts

Genomics gains momentum as EDIT, SANA, and PACB emerge as standout picks amid rapid advances in sequencing and gene editing.

Pacific Biosciences (PACB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).